Please ensure Javascript is enabled for purposes of website accessibility

Sanofi to Sell Its 20.6% Stake in Regeneron, but Keep Their Collaboration Intact

By Brian Orelli, PhD – Updated May 26, 2020 at 4:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The sale appears to be more about Sanofi's capital needs than about Regeneron's valuation.

Sanofi (SNY 0.05%) plans to sell most of its stake in longtime partner Regeneron Pharmaceuticals (REGN -0.43%). The French drugmaker currently owns 20.6% of the American biotech -- about 23.2 million shares.

Regeneron and Sanofi currently co-market eczema treatment Dupixent, rheumatoid arthritis treatment Kevzara, and cancer treatment Libtayo. And the companies have a long-term pact to develop additional drugs. None of that will change after Sanofi sells its shares.

Pen and magnifying glass on a balance sheet

Image source: Getty Images.

Instead, the decision seems to be tied to Sanofi's desire to raise capital. Regeneron plans to repurchase $5 billion of Sanofi's shares about 8.8 million or so; the rest will be sold to the public, potentially generating around $13 billion for Sanofi.

Sanofi plans to hold onto a token 400,000 shares "in support of the ongoing collaboration with Regeneron." Reducing its ownership to that minimal level will allow Sanofi to stop accounting for its stake in Regeneron, which Sanofi estimates will result in its earnings per share EPS growing by 5% year over year in 2020 at constant exchange rates.

Shares of Regeneron were down 4.2% at 12:39 p.m. EDT on Tuesday, presumably because some investors have been hoping -- for a really, really long time -- that Sanofi would acquire Regeneron. While the chances of a buyout at a premium are reduced, the share repurchase will boost Regeneron's EPS, and if the partnership truly remains intact, it really doesn't matter whether Sanofi or other investors own the rest of those shares.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
$38.02 (0.05%) $0.02
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
$688.87 (-0.43%) $-2.95

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.